Edition:
United Kingdom

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

6.00USD
22 May 2018
Change (% chg)

$-0.07 (-1.15%)
Prev Close
$6.07
Open
$6.00
Day's High
$6.00
Day's Low
$6.00
Volume
1,670
Avg. Vol
16,684
52-wk High
$12.00
52-wk Low
$3.61

Chart for

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate,... (more)

Overall

Beta: 2.71
Market Cap(Mil.): $92.69
Shares Outstanding(Mil.): 15.44
Dividend: --
Yield (%): --

Financials

  GLMD.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -0.99 -- --
ROI: -88.91 -7.38 12.74
ROE: -91.54 -10.11 14.64

BRIEF-Galmed Pharmaceuticals Q1 Loss Per Share $0.17

* GALMED PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Galmed Pharmaceuticals To Report First Quarter 2018 Financial Results And Provide Business Update On Wednesday, May 9

* GALMED PHARMACEUTICALS TO REPORT FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON WEDNESDAY, MAY 9 Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Galmed Pharmaceuticals Announces Pricing Of $6 Mln Registered Direct Offering

* ANNOUNCES PRICING OF $6.0 MILLION REGISTERED DIRECT OFFERING

03 Apr 2018

BRIEF-Galmed Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* GALMED PHARMACEUTICALS LTD FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text: [https://bit.ly/2G8U5GO] Further company coverage:

26 Mar 2018

BRIEF-Galmed Pharmaceuticals Q4 Loss Per Share $0.27

* GALMED PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

13 Mar 2018

BRIEF-Galmed Announces Arrive Study Data

* TOP-LINE RESULTS FROM ARRIVE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT

14 Feb 2018

BRIEF-Galmed Pharmaceuticals To Provide Corporate Update At The Leerink Partners 7Th Annual Global Healthcare Conference

* GALMED PHARMACEUTICALS TO PROVIDE CORPORATE UPDATE AT THE LEERINK PARTNERS 7TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Source text for Eikon: Further company coverage:

08 Feb 2018

BRIEF-Israeli Tax Authority Issues Tax Ruling On Galmed Pharma's Unit

* GALMED PHARMACEUTICALS -ISRAELI TAX AUTHORITY ISSUED TAX RULING GRANTING CO'S UNIT "PREFERRED TECHNOLOGICAL ENTERPRISE" STATUS, SUBJECT TO CONDITIONS

07 Feb 2018

BRIEF-Galmed Pharma Raised Gross Proceeds Of $11.6 Mln Under ATM Programs During Dec. 2017

* GALMED PHARMACEUTICALS RAISED GROSS PROCEEDS OF $11.6 MILLION UNDER ATM PROGRAMS DURING DECEMBER 2017 Source text for Eikon: Further company coverage:

02 Jan 2018

BRIEF-683 Capital Management Llc Reports 5.1 Pct Passive Stake In Galmed Pharmaceuticals Ltd As Of Dec 6

* 683 CAPITAL MANAGEMENT LLC REPORTS 5.1 PERCENT PASSIVE STAKE IN GALMED PHARMACEUTICALS LTD AS OF DEC 6 - SEC FILING Source text: (http://bit.ly/2oG4CRl) Further company coverage:

18 Dec 2017

Earnings vs. Estimates